Fludarabine-Melphalan with Post-Transplant Cyclophosphamide for Haploidentical Transplant in AML
For adult AML patients undergoing haploidentical stem cell transplantation, the recommended conditioning regimen is fludarabine 30 mg/m² daily for 5 days combined with melphalan 140 mg/m² on day -1, followed by post-transplant cyclophosphamide 50 mg/kg on days +3 and +4 for GVHD prophylaxis.
Conditioning Regimen Details
The fludarabine-melphalan (FluMel) regimen with post-transplant cyclophosphamide (PTCy) has emerged as an effective reduced-intensity conditioning approach for haploidentical transplants in AML:
Specific Dosing Protocol
- Fludarabine: 30 mg/m² IV daily × 5 days (days -6 to -2) 1
- Melphalan: 140 mg/m² IV on day -1 1
- Post-transplant cyclophosphamide: 50 mg/kg IV on days +3 and +4 1
GVHD Prophylaxis Beyond PTCy
Complete the GVHD prophylaxis with:
- Mycophenolate mofetil starting day +5, continuing through day +35
- Tacrolimus starting day +5, continuing through day +180 1
Clinical Outcomes and Evidence Quality
The FluMel-PTCy regimen demonstrates robust efficacy in haploidentical AML transplants with acceptable toxicity:
Survival and Disease Control
A prospective phase II trial showed 2-year outcomes of:
- Overall survival: 56%
- Disease-free survival: 44%
- Non-relapse mortality: 20%
- Relapse rate: 36% 1
Importantly, these outcomes were statistically equivalent to non-ablative fludarabine/cyclophosphamide/TBI regimens, suggesting FluMel-PTCy provides comparable disease control with potentially less toxicity 1.
GVHD Rates
The regimen produces favorable GVHD profiles:
- Grade II-IV acute GVHD: 20%
- Grade III-IV acute GVHD: 8%
- 2-year chronic GVHD: 16% (moderate-severe 12%) 1
These rates are notably lower than historical haploidentical transplant data, validating the PTCy approach.
Donor Selection Considerations
Recent data reveals that donor age is the most critical factor when using FluMel-PTCy conditioning. Donors ≥35 years are associated with:
- Lower overall survival (HR not specified but statistically significant)
- Lower GRFS
- Higher 2-year non-relapse mortality 2
Prioritize donors <35 years of age when multiple haploidentical options exist, as this appears more impactful than degree of HLA matching with this specific regimen 2.
Patient Selection and Intensity Considerations
When to Use FluMel vs. Myeloablative Conditioning
While ESMO guidelines recommend myeloablative conditioning (MAC) for fit AML patients ≤55 years with HCT-CI <2 3, FluMel-PTCy serves as an appropriate alternative when:
- Age >55 years
- HCT-CI ≥2
- Comorbidities preclude full MAC
- Patient preference for reduced toxicity with comparable outcomes
For MRD-positive AML patients specifically, FluMel produces comparable outcomes to radiation-based MAC (24-month OS 38% vs 60%, p=0.21; CIR 42% vs 35%, p=0.59), making it a reasonable option when MAC is not feasible 4.
Fludarabine Dosing Nuance
While the standard FluMel protocol uses fludarabine 150 mg/m² total dose (30 mg/m² × 5 days), emerging data suggests lower cumulative fludarabine doses (110-130 mg/m²) may improve outcomes in older AML patients with better leukemia-free survival (HR 1.46) and GRFS (HR 1.50) 5. However, this applies to RIC regimens broadly and requires validation specifically for the FluMel-PTCy haploidentical platform.
Renal Adjustment Requirements
Critical caveat: Fludarabine requires dose reduction for renal impairment 6:
- CrCl 50-79 mL/min: Reduce to 20 mg/m²/day
- CrCl 30-49 mL/min: Reduce to 15 mg/m²/day
- CrCl <30 mL/min: Do not administer 6
Calculate creatinine clearance before initiating conditioning and monitor closely for excessive toxicity.
Graft Source
Use peripheral blood stem cells (PBSC), not bone marrow, for this regimen. The prospective trial establishing FluMel-PTCy efficacy specifically utilized unmanipulated PBSC grafts 1. While original haploidentical PTCy protocols used bone marrow, PBSC with this conditioning intensity provides faster engraftment (median 18 days to neutrophils, 36 days to platelets) without prohibitive GVHD rates 1.
High-Risk Disease Considerations
For patients with high/very high Disease Risk Index, 2-year OS remains 53% with FluMel-PTCy 1. While this is lower than intermediate-risk patients (69%), it still represents meaningful disease control in an otherwise poor-prognosis population. Do not withhold haploidentical transplant with FluMel-PTCy conditioning based solely on adverse disease risk, as alternative options are limited and outcomes remain superior to non-transplant approaches.